Home » Products » Insulin Glargine Injection 100IU/mL 3ml Cartridge | GMP Manufacturer & Supplier | Sinophare
- Dosage: 100 IU/mL, 3ml cartridge
- Volume: 3ml cartridge
- Packaging: Sterile cartridge for injection, 3ml cartridge/tray*1 box*10/catron
- Shelf Life: 36 months
Package:
Product Description
| Product Name | Insulin Glargine Injection (Long-Acting Basal Insulin Analogue, Recombinant DNA Origin) |
| Specification | 100 IU/mL — 3mL Cartridge (300 IU total) |
| Dosage Form | Sterile, Nonpyrogenic, Clear, Colorless Aqueous Solution for Subcutaneous Injection (long-acting basal insulin analogue) |
| Active Ingredient | Insulin Glargine (recombinant DNA origin; human insulin analogue with A21 glycine substitution and two additional arginine residues at B30) |
| Pharmacological Class | Antidiabetic Agent / Pancreatic Hormone / Long-Acting Basal Insulin Analogue (Blood Glucose Regulating Agent) |
| Route of Administration | Subcutaneous injection only (abdomen, thigh, deltoid, or buttock). NOT for intravenous or intramuscular injection. NOT to be mixed with any other insulin formulation. |
| Packaging | 3mL glass cartridge (for use with compatible insulin pen devices) |
| Storage | Unopened: Store refrigerated at 2°C to 8°C, protected from light. Do NOT freeze. In-use (opened): Store at room temperature (below 25°C) for up to 28 days, away from direct heat and light. Discard after 28 days even if unused. |
| Shelf Life | 36 months (unopened, refrigerated) |
Product Overview
Insulin Glargine Injection 100IU/mL 3mL Cartridge is a sterile, nonpyrogenic, clear, colorless aqueous solution of insulin glargine intended for subcutaneous injection. Each 3mL glass cartridge contains 300 IU (100 IU/mL) of insulin glargine. Insulin glargine is a long-acting basal insulin analogue produced by recombinant DNA technology, with specific amino acid modifications designed to provide a prolonged, peakless glucose-lowering profile. The product is formulated as a clear, acidic solution (pH approximately 4.0) in which insulin glargine remains fully soluble; upon subcutaneous injection into physiological pH tissue, the insulin glargine forms microprecipitates that slowly release insulin over an extended period, providing stable basal glycemic control.
